Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 126 | 2024 | 5314 | 8.460 |
Why?
|
Lung Neoplasms | 186 | 2024 | 13381 | 7.620 |
Why?
|
Quinazolines | 45 | 2016 | 1371 | 3.800 |
Why?
|
Proto-Oncogene Proteins B-raf | 18 | 2024 | 2057 | 3.340 |
Why?
|
Carcinoma, Small Cell | 20 | 2008 | 420 | 2.940 |
Why?
|
Protein Kinase Inhibitors | 37 | 2023 | 5672 | 2.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 36 | 2024 | 11742 | 2.020 |
Why?
|
Mutation | 71 | 2024 | 30053 | 1.560 |
Why?
|
Antineoplastic Agents | 49 | 2020 | 13642 | 1.530 |
Why?
|
Oximes | 5 | 2021 | 303 | 1.430 |
Why?
|
Pyrimidinones | 4 | 2021 | 385 | 1.250 |
Why?
|
Adenocarcinoma | 30 | 2017 | 6345 | 1.220 |
Why?
|
Imidazoles | 6 | 2021 | 1180 | 1.190 |
Why?
|
Tumor Burden | 12 | 2023 | 1892 | 1.160 |
Why?
|
Pyridones | 4 | 2021 | 809 | 1.020 |
Why?
|
Carbamates | 2 | 2024 | 191 | 0.990 |
Why?
|
Carcinoma, Large Cell | 4 | 2016 | 113 | 0.940 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 7 | 2012 | 89 | 0.930 |
Why?
|
Genes, erbB-1 | 7 | 2015 | 162 | 0.820 |
Why?
|
Benzimidazoles | 2 | 2024 | 858 | 0.760 |
Why?
|
Receptors, Adrenergic, beta-2 | 3 | 2007 | 215 | 0.750 |
Why?
|
Neoplasm Staging | 34 | 2020 | 11120 | 0.740 |
Why?
|
Research Subjects | 1 | 2021 | 249 | 0.660 |
Why?
|
Pulmonary Gas Exchange | 2 | 2012 | 379 | 0.660 |
Why?
|
Middle Aged | 126 | 2024 | 220921 | 0.630 |
Why?
|
Aged | 114 | 2024 | 169310 | 0.630 |
Why?
|
Humans | 251 | 2024 | 761596 | 0.630 |
Why?
|
Carcinoid Tumor | 2 | 2014 | 224 | 0.620 |
Why?
|
Neoplasm Metastasis | 10 | 2024 | 4915 | 0.600 |
Why?
|
Genomics | 17 | 2024 | 5821 | 0.590 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 12 | 2024 | 1745 | 0.580 |
Why?
|
Exercise Test | 7 | 2012 | 2127 | 0.580 |
Why?
|
Aged, 80 and over | 58 | 2024 | 58984 | 0.580 |
Why?
|
Clinical Trials as Topic | 13 | 2024 | 8002 | 0.570 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2014 | 4024 | 0.560 |
Why?
|
Sulfonamides | 2 | 2024 | 1979 | 0.550 |
Why?
|
Survival Analysis | 27 | 2021 | 10090 | 0.550 |
Why?
|
Male | 143 | 2024 | 360846 | 0.540 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2014 | 326 | 0.540 |
Why?
|
Receptor Protein-Tyrosine Kinases | 9 | 2022 | 1626 | 0.530 |
Why?
|
Female | 150 | 2024 | 392705 | 0.520 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2020 | 9280 | 0.510 |
Why?
|
Adult | 90 | 2024 | 221210 | 0.490 |
Why?
|
Neoplasms | 18 | 2024 | 22173 | 0.490 |
Why?
|
Pulmonary Diffusing Capacity | 4 | 2008 | 94 | 0.490 |
Why?
|
Disease-Free Survival | 15 | 2017 | 6815 | 0.490 |
Why?
|
Receptor, erbB-2 | 9 | 2023 | 2557 | 0.480 |
Why?
|
Prognosis | 34 | 2021 | 29629 | 0.480 |
Why?
|
Single-Cell Analysis | 7 | 2024 | 2451 | 0.470 |
Why?
|
Piperidines | 9 | 2015 | 1656 | 0.470 |
Why?
|
Molecular Targeted Therapy | 13 | 2024 | 2811 | 0.470 |
Why?
|
Drug Resistance, Neoplasm | 15 | 2023 | 5305 | 0.470 |
Why?
|
Proto-Oncogene Proteins c-met | 11 | 2019 | 571 | 0.460 |
Why?
|
Pleural Neoplasms | 6 | 2018 | 609 | 0.460 |
Why?
|
Central Nervous System Neoplasms | 4 | 2012 | 916 | 0.440 |
Why?
|
Mesothelioma | 7 | 2018 | 807 | 0.430 |
Why?
|
Pneumonectomy | 5 | 2012 | 1119 | 0.410 |
Why?
|
Biostatistics | 1 | 2014 | 164 | 0.410 |
Why?
|
Survival Rate | 17 | 2021 | 12723 | 0.400 |
Why?
|
Medical Oncology | 3 | 2019 | 2321 | 0.400 |
Why?
|
Smoking | 8 | 2021 | 9053 | 0.390 |
Why?
|
DNA Mutational Analysis | 17 | 2017 | 4111 | 0.390 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 474 | 0.390 |
Why?
|
Proto-Oncogene Proteins | 12 | 2016 | 4514 | 0.390 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 422 | 0.370 |
Why?
|
Treatment Outcome | 47 | 2024 | 64685 | 0.370 |
Why?
|
Disease Progression | 21 | 2016 | 13510 | 0.370 |
Why?
|
Sample Size | 1 | 2014 | 841 | 0.370 |
Why?
|
ras Proteins | 5 | 2014 | 1054 | 0.360 |
Why?
|
Paraneoplastic Syndromes | 3 | 2006 | 155 | 0.340 |
Why?
|
Oncogene Proteins | 2 | 2013 | 719 | 0.340 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2020 | 423 | 0.330 |
Why?
|
Melanoma | 3 | 2023 | 5709 | 0.330 |
Why?
|
Taxoids | 5 | 2013 | 668 | 0.320 |
Why?
|
Glycine | 3 | 2007 | 663 | 0.320 |
Why?
|
Vascular Endothelial Growth Factor A | 6 | 2015 | 3492 | 0.310 |
Why?
|
Tumor Microenvironment | 6 | 2024 | 3878 | 0.310 |
Why?
|
Angiogenesis Inhibitors | 3 | 2014 | 2048 | 0.300 |
Why?
|
American Cancer Society | 2 | 2024 | 69 | 0.300 |
Why?
|
Antibodies, Monoclonal | 9 | 2010 | 9177 | 0.290 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2024 | 3639 | 0.290 |
Why?
|
Tomography, X-Ray Computed | 15 | 2022 | 20568 | 0.290 |
Why?
|
Heart Failure | 6 | 2010 | 11671 | 0.290 |
Why?
|
Cohort Studies | 18 | 2022 | 41495 | 0.290 |
Why?
|
Social Control, Informal | 1 | 2008 | 44 | 0.290 |
Why?
|
Carbon Dioxide | 1 | 2012 | 1147 | 0.290 |
Why?
|
Forced Expiratory Flow Rates | 1 | 2007 | 75 | 0.280 |
Why?
|
Smoking Cessation | 5 | 2012 | 2057 | 0.280 |
Why?
|
Piperazines | 5 | 2007 | 2523 | 0.280 |
Why?
|
Pyrimidines | 6 | 2013 | 3028 | 0.280 |
Why?
|
Maximum Tolerated Dose | 6 | 2017 | 883 | 0.280 |
Why?
|
Tumor Escape | 2 | 2021 | 370 | 0.280 |
Why?
|
Genital Diseases, Female | 1 | 2008 | 192 | 0.280 |
Why?
|
Visual Acuity | 1 | 2016 | 2672 | 0.270 |
Why?
|
Law Enforcement | 1 | 2008 | 112 | 0.270 |
Why?
|
Phosphatidylinositol 3-Kinases | 9 | 2023 | 2865 | 0.260 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1069 | 0.260 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2018 | 2510 | 0.260 |
Why?
|
Cardiac Output, Low | 1 | 2006 | 191 | 0.260 |
Why?
|
Police | 1 | 2008 | 157 | 0.260 |
Why?
|
Enzyme Inhibitors | 6 | 2012 | 3713 | 0.260 |
Why?
|
Arginine | 2 | 2006 | 934 | 0.260 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 2828 | 0.250 |
Why?
|
Paclitaxel | 8 | 2013 | 1732 | 0.250 |
Why?
|
Medically Underserved Area | 1 | 2008 | 254 | 0.250 |
Why?
|
Gene Expression Regulation, Neoplastic | 14 | 2024 | 8554 | 0.250 |
Why?
|
Deoxyribonuclease I | 1 | 2006 | 224 | 0.250 |
Why?
|
Sirolimus | 3 | 2012 | 1533 | 0.250 |
Why?
|
Sequence Analysis, RNA | 7 | 2024 | 2021 | 0.250 |
Why?
|
Retinal Artery Occlusion | 1 | 2005 | 77 | 0.240 |
Why?
|
Family Practice | 1 | 2008 | 512 | 0.240 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 3617 | 0.240 |
Why?
|
Cisplatin | 4 | 2018 | 1652 | 0.240 |
Why?
|
Marijuana Smoking | 1 | 2008 | 258 | 0.230 |
Why?
|
Retrospective Studies | 31 | 2023 | 80647 | 0.230 |
Why?
|
Data Interpretation, Statistical | 1 | 2014 | 2691 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-kit | 4 | 2005 | 727 | 0.230 |
Why?
|
Sunburn | 1 | 2005 | 156 | 0.230 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 86 | 0.230 |
Why?
|
Rural Health Services | 1 | 2008 | 384 | 0.230 |
Why?
|
Sodium Chloride | 1 | 2006 | 587 | 0.230 |
Why?
|
Administration, Oral | 7 | 2017 | 4021 | 0.230 |
Why?
|
Erythema | 1 | 2005 | 262 | 0.220 |
Why?
|
Hypertension, Pulmonary | 2 | 2012 | 1578 | 0.220 |
Why?
|
Patient Preference | 1 | 2011 | 927 | 0.210 |
Why?
|
Hyponatremia | 1 | 2006 | 279 | 0.210 |
Why?
|
Lung | 6 | 2020 | 10002 | 0.210 |
Why?
|
Combined Modality Therapy | 10 | 2018 | 8527 | 0.210 |
Why?
|
Gene Rearrangement | 3 | 2016 | 1125 | 0.210 |
Why?
|
SEER Program | 4 | 2019 | 1450 | 0.210 |
Why?
|
Meningeal Neoplasms | 2 | 2015 | 1248 | 0.210 |
Why?
|
Mutagenesis, Insertional | 2 | 2017 | 656 | 0.210 |
Why?
|
Head and Neck Neoplasms | 4 | 2011 | 2894 | 0.200 |
Why?
|
Leptin | 2 | 2008 | 1597 | 0.200 |
Why?
|
Guidelines as Topic | 2 | 2009 | 1386 | 0.200 |
Why?
|
Genome, Human | 3 | 2012 | 4425 | 0.200 |
Why?
|
Genotype | 9 | 2015 | 12990 | 0.190 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2003 | 857 | 0.190 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2024 | 738 | 0.190 |
Why?
|
Gene Expression Profiling | 6 | 2021 | 9420 | 0.190 |
Why?
|
Immunohistochemistry | 10 | 2019 | 11076 | 0.190 |
Why?
|
Cell Line, Tumor | 22 | 2021 | 16990 | 0.190 |
Why?
|
Apolipoproteins E | 1 | 2007 | 1443 | 0.190 |
Why?
|
Genes, erbB-2 | 3 | 2017 | 162 | 0.190 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 546 | 0.190 |
Why?
|
Edema | 1 | 2005 | 766 | 0.190 |
Why?
|
Cell Proliferation | 7 | 2015 | 10451 | 0.180 |
Why?
|
Exons | 6 | 2019 | 2391 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2018 | 899 | 0.180 |
Why?
|
Heart Rate | 3 | 2009 | 4195 | 0.180 |
Why?
|
Quinolones | 1 | 2004 | 378 | 0.180 |
Why?
|
Sodium | 1 | 2006 | 1588 | 0.180 |
Why?
|
Drug Therapy, Combination | 3 | 2018 | 6312 | 0.180 |
Why?
|
Patient Selection | 3 | 2012 | 4244 | 0.180 |
Why?
|
Brain Neoplasms | 7 | 2022 | 9032 | 0.180 |
Why?
|
Respiratory Mucosa | 1 | 2003 | 439 | 0.180 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2012 | 3514 | 0.170 |
Why?
|
Thoracic Neoplasms | 1 | 2022 | 267 | 0.170 |
Why?
|
Oxygen | 1 | 2012 | 4227 | 0.170 |
Why?
|
Genes, ras | 6 | 2015 | 654 | 0.170 |
Why?
|
Off-Label Use | 1 | 2022 | 185 | 0.170 |
Why?
|
Gene Amplification | 6 | 2014 | 1089 | 0.170 |
Why?
|
Cystadenoma, Serous | 1 | 2020 | 100 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2017 | 10766 | 0.170 |
Why?
|
Follow-Up Studies | 16 | 2019 | 39106 | 0.170 |
Why?
|
Molecular Imaging | 2 | 2021 | 815 | 0.170 |
Why?
|
Preoperative Care | 1 | 2008 | 2242 | 0.160 |
Why?
|
Pneumothorax | 1 | 2022 | 386 | 0.160 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2003 | 621 | 0.160 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2021 | 1728 | 0.160 |
Why?
|
Breast Neoplasms, Male | 1 | 2020 | 219 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 7 | 2020 | 6484 | 0.160 |
Why?
|
Health Services | 1 | 2004 | 752 | 0.160 |
Why?
|
Life Expectancy | 1 | 2005 | 1243 | 0.150 |
Why?
|
Genes, p53 | 3 | 2012 | 712 | 0.150 |
Why?
|
Ascites | 1 | 2020 | 338 | 0.150 |
Why?
|
Receptor, erbB-3 | 4 | 2007 | 143 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2009 | 1784 | 0.150 |
Why?
|
Carboplatin | 7 | 2013 | 794 | 0.150 |
Why?
|
MAP Kinase Kinase 1 | 4 | 2015 | 332 | 0.140 |
Why?
|
BRCA2 Protein | 1 | 2022 | 805 | 0.140 |
Why?
|
Amino Acid Substitution | 3 | 2018 | 1739 | 0.140 |
Why?
|
Genetic Testing | 3 | 2022 | 3537 | 0.140 |
Why?
|
Pteridines | 1 | 2016 | 47 | 0.140 |
Why?
|
Precancerous Conditions | 1 | 2003 | 980 | 0.140 |
Why?
|
Alleles | 2 | 2024 | 6864 | 0.140 |
Why?
|
Biopsy | 5 | 2024 | 6766 | 0.140 |
Why?
|
DNA, Neoplasm | 5 | 2016 | 1745 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2016 | 2425 | 0.130 |
Why?
|
Hyperthermia, Induced | 2 | 2018 | 417 | 0.130 |
Why?
|
Health Plan Implementation | 1 | 2019 | 337 | 0.130 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2007 | 2118 | 0.130 |
Why?
|
Deoxycytidine | 2 | 2018 | 877 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1126 | 0.130 |
Why?
|
Mutation, Missense | 4 | 2013 | 2571 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2003 | 1052 | 0.130 |
Why?
|
Sulfones | 3 | 2007 | 448 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 350 | 0.130 |
Why?
|
Positron-Emission Tomography | 4 | 2022 | 6484 | 0.130 |
Why?
|
BRCA1 Protein | 1 | 2022 | 1158 | 0.130 |
Why?
|
Receptor, trkA | 1 | 2016 | 159 | 0.120 |
Why?
|
Respiratory Function Tests | 4 | 2009 | 1682 | 0.120 |
Why?
|
Protein Structure, Tertiary | 6 | 2008 | 3792 | 0.120 |
Why?
|
Dimerization | 2 | 2007 | 891 | 0.120 |
Why?
|
Prospective Studies | 14 | 2021 | 54423 | 0.120 |
Why?
|
Ovarian Neoplasms | 2 | 2023 | 4878 | 0.120 |
Why?
|
Confidence Intervals | 2 | 2017 | 2927 | 0.120 |
Why?
|
Proportional Hazards Models | 6 | 2013 | 12463 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 561 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4853 | 0.120 |
Why?
|
Social Class | 1 | 2004 | 2004 | 0.120 |
Why?
|
Minnesota | 4 | 2009 | 338 | 0.120 |
Why?
|
Phosphorylation | 13 | 2016 | 8321 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2015 | 10212 | 0.120 |
Why?
|
Genes, p16 | 2 | 2012 | 160 | 0.120 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2009 | 629 | 0.120 |
Why?
|
Polymerase Chain Reaction | 3 | 2013 | 6075 | 0.120 |
Why?
|
Young Adult | 11 | 2020 | 59260 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2020 | 2827 | 0.110 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 728 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2010 | 15936 | 0.110 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 718 | 0.110 |
Why?
|
Social Support | 1 | 2004 | 2172 | 0.110 |
Why?
|
Tumor Cells, Cultured | 6 | 2020 | 6131 | 0.110 |
Why?
|
New York City | 2 | 2008 | 731 | 0.110 |
Why?
|
Apoptosis | 5 | 2006 | 9490 | 0.110 |
Why?
|
Signal Transduction | 13 | 2020 | 23447 | 0.110 |
Why?
|
Recovery of Function | 3 | 2009 | 2979 | 0.110 |
Why?
|
Registries | 1 | 2009 | 8225 | 0.110 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2015 | 2057 | 0.110 |
Why?
|
Genes, Neoplasm | 2 | 2012 | 370 | 0.110 |
Why?
|
Benzamides | 5 | 2007 | 1371 | 0.100 |
Why?
|
United States | 13 | 2024 | 72340 | 0.100 |
Why?
|
Breast Neoplasms | 5 | 2024 | 21019 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 5 | 2024 | 17904 | 0.100 |
Why?
|
Mass Screening | 4 | 2011 | 5429 | 0.100 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2015 | 732 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2016 | 946 | 0.100 |
Why?
|
Oxygen Consumption | 2 | 2009 | 1866 | 0.100 |
Why?
|
Feasibility Studies | 5 | 2019 | 5247 | 0.100 |
Why?
|
Pancreatic Neoplasms | 2 | 2021 | 5368 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 9 | 2015 | 2457 | 0.100 |
Why?
|
Exercise Tolerance | 3 | 2008 | 836 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2330 | 0.100 |
Why?
|
Case-Control Studies | 7 | 2020 | 22176 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2013 | 225 | 0.100 |
Why?
|
Pneumonia | 1 | 2023 | 2143 | 0.100 |
Why?
|
Receptors, Mitogen | 1 | 2011 | 61 | 0.100 |
Why?
|
Cell Nucleus | 1 | 2020 | 2910 | 0.090 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2012 | 103 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 1660 | 0.090 |
Why?
|
Adaptive Immunity | 1 | 2016 | 726 | 0.090 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2008 | 1241 | 0.090 |
Why?
|
Epoprostenol | 1 | 2012 | 247 | 0.090 |
Why?
|
Insurance Coverage | 1 | 2022 | 1940 | 0.090 |
Why?
|
Adolescent | 11 | 2024 | 88326 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2013 | 2850 | 0.090 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2024 | 373 | 0.090 |
Why?
|
Epidermal Growth Factor | 2 | 2004 | 702 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2915 | 0.090 |
Why?
|
Genetic Variation | 3 | 2018 | 6567 | 0.090 |
Why?
|
Double-Blind Method | 4 | 2013 | 12341 | 0.090 |
Why?
|
Iohexol | 1 | 2010 | 204 | 0.080 |
Why?
|
Risk Assessment | 6 | 2012 | 23996 | 0.080 |
Why?
|
Aneuploidy | 2 | 2023 | 552 | 0.080 |
Why?
|
Thionucleotides | 1 | 2009 | 112 | 0.080 |
Why?
|
Forecasting | 1 | 2019 | 2928 | 0.080 |
Why?
|
Cytoskeleton | 3 | 2003 | 1170 | 0.080 |
Why?
|
Liver Neoplasms | 2 | 2015 | 4317 | 0.080 |
Why?
|
Lung Transplantation | 3 | 2009 | 1310 | 0.080 |
Why?
|
Sensitivity and Specificity | 8 | 2010 | 14665 | 0.080 |
Why?
|
Estrogen Receptor beta | 1 | 2010 | 168 | 0.080 |
Why?
|
Mice, Nude | 4 | 2020 | 3614 | 0.080 |
Why?
|
Health Expenditures | 1 | 2022 | 2366 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3597 | 0.080 |
Why?
|
Amifostine | 1 | 2009 | 40 | 0.080 |
Why?
|
Massachusetts | 3 | 2021 | 8833 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2578 | 0.080 |
Why?
|
Biomedical Research | 1 | 2024 | 3429 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2009 | 205 | 0.080 |
Why?
|
Withholding Treatment | 1 | 2013 | 617 | 0.080 |
Why?
|
Severity of Illness Index | 5 | 2014 | 15843 | 0.080 |
Why?
|
Thiazoles | 2 | 2013 | 1517 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 664 | 0.080 |
Why?
|
Metabolic Clearance Rate | 2 | 2006 | 361 | 0.080 |
Why?
|
Academic Medical Centers | 2 | 2022 | 2759 | 0.080 |
Why?
|
Radiation-Protective Agents | 1 | 2009 | 88 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 2917 | 0.080 |
Why?
|
Vital Capacity | 2 | 2009 | 971 | 0.080 |
Why?
|
Animals | 23 | 2021 | 168475 | 0.080 |
Why?
|
Phenylethanolamine N-Methyltransferase | 1 | 2008 | 18 | 0.080 |
Why?
|
Online Systems | 1 | 2009 | 182 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2024 | 10194 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2012 | 2264 | 0.080 |
Why?
|
Cytoprotection | 1 | 2009 | 200 | 0.080 |
Why?
|
Tobacco Use Disorder | 2 | 2011 | 703 | 0.080 |
Why?
|
Protein Multimerization | 1 | 2013 | 983 | 0.080 |
Why?
|
Algorithms | 3 | 2021 | 14033 | 0.080 |
Why?
|
Electrocardiography | 4 | 2009 | 6377 | 0.080 |
Why?
|
Analysis of Variance | 3 | 2014 | 6228 | 0.080 |
Why?
|
Heart-Lung Transplantation | 1 | 2008 | 87 | 0.080 |
Why?
|
Time Factors | 9 | 2024 | 39969 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.070 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2009 | 278 | 0.070 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1222 | 0.070 |
Why?
|
Drug Industry | 1 | 2014 | 788 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2007 | 2009 | 0.070 |
Why?
|
Lung Diseases | 2 | 2009 | 1909 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3455 | 0.070 |
Why?
|
Anthropology, Cultural | 1 | 2008 | 102 | 0.070 |
Why?
|
Observer Variation | 2 | 2010 | 2606 | 0.070 |
Why?
|
Local Government | 1 | 2008 | 81 | 0.070 |
Why?
|
Tomography, Spiral Computed | 1 | 2008 | 273 | 0.070 |
Why?
|
Risk Factors | 8 | 2013 | 74213 | 0.070 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2007 | 92 | 0.070 |
Why?
|
Poverty | 1 | 2019 | 2697 | 0.070 |
Why?
|
Substance-Related Disorders | 1 | 2004 | 4420 | 0.070 |
Why?
|
Haplotypes | 2 | 2010 | 2713 | 0.070 |
Why?
|
Friends | 1 | 2008 | 149 | 0.070 |
Why?
|
Peak Expiratory Flow Rate | 1 | 2006 | 144 | 0.070 |
Why?
|
Predictive Value of Tests | 6 | 2009 | 15266 | 0.070 |
Why?
|
Drug Design | 1 | 2012 | 1048 | 0.070 |
Why?
|
Remission Induction | 3 | 2016 | 2397 | 0.070 |
Why?
|
Parity | 1 | 2010 | 927 | 0.070 |
Why?
|
Polymorphism, Genetic | 2 | 2008 | 4243 | 0.070 |
Why?
|
Insulin Infusion Systems | 1 | 2008 | 217 | 0.070 |
Why?
|
Pyridines | 2 | 2016 | 2875 | 0.070 |
Why?
|
Recurrence | 3 | 2016 | 8466 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4016 | 0.070 |
Why?
|
Mice | 16 | 2021 | 81539 | 0.070 |
Why?
|
Models, Molecular | 4 | 2016 | 5439 | 0.070 |
Why?
|
Forced Expiratory Volume | 2 | 2009 | 1814 | 0.070 |
Why?
|
Pyrazoles | 1 | 2016 | 2009 | 0.070 |
Why?
|
Boston | 2 | 2021 | 9327 | 0.070 |
Why?
|
Receptors, Growth Factor | 1 | 2007 | 326 | 0.070 |
Why?
|
Body Mass Index | 3 | 2021 | 12953 | 0.070 |
Why?
|
Oncogenes | 2 | 2022 | 1222 | 0.070 |
Why?
|
Stereotyping | 1 | 2008 | 239 | 0.060 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 876 | 0.060 |
Why?
|
Arginine Vasopressin | 1 | 2006 | 125 | 0.060 |
Why?
|
Bone Neoplasms | 2 | 2015 | 2529 | 0.060 |
Why?
|
Inhibitory Concentration 50 | 2 | 2005 | 465 | 0.060 |
Why?
|
Sex Factors | 4 | 2015 | 10554 | 0.060 |
Why?
|
Loss of Heterozygosity | 2 | 2007 | 662 | 0.060 |
Why?
|
Lung Volume Measurements | 1 | 2006 | 375 | 0.060 |
Why?
|
Leg Dermatoses | 1 | 2005 | 20 | 0.060 |
Why?
|
Government Programs | 1 | 2008 | 279 | 0.060 |
Why?
|
NIH 3T3 Cells | 3 | 2013 | 670 | 0.060 |
Why?
|
Family Relations | 1 | 2008 | 317 | 0.060 |
Why?
|
Intraoperative Care | 1 | 2009 | 767 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 3449 | 0.060 |
Why?
|
Germ-Line Mutation | 3 | 2022 | 1858 | 0.060 |
Why?
|
Prevalence | 3 | 2024 | 15733 | 0.060 |
Why?
|
Atrial Natriuretic Factor | 1 | 2006 | 350 | 0.060 |
Why?
|
Paraffin Embedding | 1 | 2006 | 302 | 0.060 |
Why?
|
Gene Deletion | 1 | 2012 | 2665 | 0.060 |
Why?
|
Physical Exertion | 1 | 2007 | 667 | 0.060 |
Why?
|
Biopsy, Needle | 2 | 2006 | 1626 | 0.060 |
Why?
|
Cyclic GMP | 1 | 2006 | 395 | 0.060 |
Why?
|
Walking | 1 | 2012 | 1198 | 0.060 |
Why?
|
Epinephrine | 1 | 2008 | 792 | 0.060 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 71 | 0.060 |
Why?
|
Blood Gas Analysis | 1 | 2005 | 379 | 0.060 |
Why?
|
Hepatocyte Growth Factor | 2 | 2005 | 271 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2018 | 20100 | 0.060 |
Why?
|
Infusions, Intravenous | 2 | 2006 | 2217 | 0.060 |
Why?
|
Formaldehyde | 1 | 2006 | 358 | 0.060 |
Why?
|
Medical History Taking | 1 | 2008 | 774 | 0.060 |
Why?
|
Antibodies, Neoplasm | 1 | 2005 | 281 | 0.060 |
Why?
|
Schools, Medical | 1 | 2010 | 879 | 0.060 |
Why?
|
Antilymphocyte Serum | 1 | 2005 | 487 | 0.060 |
Why?
|
Nuclear Proteins | 3 | 2023 | 5799 | 0.050 |
Why?
|
Public Policy | 1 | 2008 | 559 | 0.050 |
Why?
|
Ventricular Function, Right | 1 | 2007 | 617 | 0.050 |
Why?
|
Blood Pressure | 3 | 2009 | 8481 | 0.050 |
Why?
|
Genes, MDR | 1 | 2003 | 36 | 0.050 |
Why?
|
Pulmonary Ventilation | 1 | 2005 | 372 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2012 | 1723 | 0.050 |
Why?
|
Denmark | 1 | 2005 | 771 | 0.050 |
Why?
|
Echocardiography, Doppler | 1 | 2007 | 897 | 0.050 |
Why?
|
Molecular Biology | 1 | 2006 | 576 | 0.050 |
Why?
|
Counseling | 1 | 2011 | 1547 | 0.050 |
Why?
|
Practice Guidelines as Topic | 3 | 2010 | 7391 | 0.050 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2003 | 105 | 0.050 |
Why?
|
Louisiana | 1 | 2022 | 103 | 0.050 |
Why?
|
Diagnostic Tests, Routine | 1 | 2008 | 787 | 0.050 |
Why?
|
Spirometry | 1 | 2005 | 929 | 0.050 |
Why?
|
Myocardial Contraction | 1 | 2007 | 1515 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1246 | 0.050 |
Why?
|
Peer Group | 1 | 2008 | 692 | 0.050 |
Why?
|
Illinois | 1 | 2022 | 120 | 0.050 |
Why?
|
Transcription Factors | 4 | 2023 | 12130 | 0.050 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2006 | 1541 | 0.050 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2024 | 0.050 |
Why?
|
Research | 3 | 2010 | 1982 | 0.050 |
Why?
|
Cyclic AMP | 1 | 2006 | 1463 | 0.050 |
Why?
|
Homozygote | 1 | 2006 | 1776 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 330 | 0.050 |
Why?
|
Radiotherapy, High-Energy | 1 | 2002 | 228 | 0.050 |
Why?
|
Tacrolimus | 1 | 2005 | 733 | 0.050 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2010 | 1609 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6938 | 0.050 |
Why?
|
Italy | 1 | 2003 | 842 | 0.050 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2008 | 1651 | 0.050 |
Why?
|
Contrast Media | 2 | 2014 | 5307 | 0.050 |
Why?
|
DNA Copy Number Variations | 2 | 2020 | 2020 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26129 | 0.050 |
Why?
|
Aldosterone | 1 | 2006 | 870 | 0.050 |
Why?
|
Cell Division | 3 | 2003 | 4465 | 0.050 |
Why?
|
Indoles | 2 | 2007 | 1833 | 0.050 |
Why?
|
Proto-Oncogenes | 2 | 2014 | 321 | 0.050 |
Why?
|
Glycoproteins | 1 | 2008 | 2203 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 384 | 0.050 |
Why?
|
Immunoenzyme Techniques | 1 | 2003 | 1704 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2011 | 2319 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2021 | 3549 | 0.040 |
Why?
|
Cell Cycle | 3 | 2005 | 2932 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 2007 | 1302 | 0.040 |
Why?
|
Protein Kinases | 1 | 2007 | 1608 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3810 | 0.040 |
Why?
|
Janus Kinase 1 | 1 | 2020 | 107 | 0.040 |
Why?
|
Image Enhancement | 1 | 2011 | 2884 | 0.040 |
Why?
|
Heterozygote | 1 | 2007 | 2787 | 0.040 |
Why?
|
Chromosomes | 1 | 2023 | 578 | 0.040 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2020 | 102 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3688 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3530 | 0.040 |
Why?
|
Treatment Failure | 2 | 2016 | 2643 | 0.040 |
Why?
|
STAT Transcription Factors | 1 | 2020 | 188 | 0.040 |
Why?
|
Heart Atria | 1 | 2005 | 1345 | 0.040 |
Why?
|
Freezing | 1 | 2020 | 311 | 0.040 |
Why?
|
Postoperative Complications | 4 | 2009 | 15633 | 0.040 |
Why?
|
Dendritic Spines | 1 | 2021 | 243 | 0.040 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 2567 | 0.040 |
Why?
|
Immunophenotyping | 1 | 2024 | 1869 | 0.040 |
Why?
|
Genes, myc | 1 | 2020 | 390 | 0.040 |
Why?
|
Atlases as Topic | 1 | 2020 | 248 | 0.040 |
Why?
|
Health Promotion | 1 | 2011 | 2214 | 0.040 |
Why?
|
Education, Medical | 1 | 2010 | 1725 | 0.040 |
Why?
|
Sequence Analysis, DNA | 3 | 2019 | 4740 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2008 | 1303 | 0.040 |
Why?
|
Computational Biology | 2 | 2021 | 3517 | 0.040 |
Why?
|
Random Allocation | 1 | 2003 | 2395 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2003 | 1702 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2021 | 428 | 0.040 |
Why?
|
Blotting, Western | 4 | 2009 | 5035 | 0.040 |
Why?
|
Risk | 1 | 2010 | 9610 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2005 | 1784 | 0.040 |
Why?
|
Databases, Factual | 2 | 2014 | 7968 | 0.040 |
Why?
|
Cell Movement | 5 | 2015 | 5205 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2021 | 802 | 0.040 |
Why?
|
Receptors, CXCR4 | 1 | 2002 | 727 | 0.040 |
Why?
|
Germ Cells | 1 | 2021 | 634 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1051 | 0.040 |
Why?
|
Placebos | 3 | 2007 | 1667 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 851 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2022 | 1076 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 959 | 0.040 |
Why?
|
Imaging, Three-Dimensional | 1 | 2010 | 4062 | 0.040 |
Why?
|
Cytokines | 2 | 2009 | 7396 | 0.040 |
Why?
|
Area Under Curve | 1 | 2021 | 1638 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2021 | 1341 | 0.030 |
Why?
|
Curriculum | 1 | 2010 | 3743 | 0.030 |
Why?
|
Coronary Artery Disease | 2 | 2008 | 6403 | 0.030 |
Why?
|
Interferon-gamma | 2 | 2021 | 3162 | 0.030 |
Why?
|
MAP Kinase Signaling System | 2 | 2018 | 1486 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2023 | 1768 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1406 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2021 | 823 | 0.030 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2005 | 1310 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 842 | 0.030 |
Why?
|
Graft Rejection | 2 | 2008 | 4446 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2021 | 1007 | 0.030 |
Why?
|
Stromal Cells | 1 | 2021 | 1330 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3779 | 0.030 |
Why?
|
Base Sequence | 2 | 2022 | 12441 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 996 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3085 | 0.030 |
Why?
|
Heart Ventricles | 1 | 2007 | 3807 | 0.030 |
Why?
|
Computer Simulation | 1 | 2008 | 6241 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1092 | 0.030 |
Why?
|
Radiotherapy | 1 | 2002 | 1498 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2016 | 544 | 0.030 |
Why?
|
Coronary Disease | 1 | 2009 | 5914 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2206 | 0.030 |
Why?
|
Data Collection | 1 | 2004 | 3322 | 0.030 |
Why?
|
Transfection | 3 | 2009 | 5774 | 0.030 |
Why?
|
Epitopes | 1 | 2021 | 2503 | 0.030 |
Why?
|
Chromones | 2 | 2005 | 148 | 0.030 |
Why?
|
Child | 4 | 2024 | 80158 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2015 | 2707 | 0.030 |
Why?
|
RNA Interference | 3 | 2007 | 2832 | 0.030 |
Why?
|
Ultrasonography | 1 | 2007 | 5971 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 2 | 2008 | 1062 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 473 | 0.030 |
Why?
|
Insulin | 1 | 2008 | 6597 | 0.030 |
Why?
|
Comorbidity | 1 | 2008 | 10508 | 0.030 |
Why?
|
Electronic Health Records | 2 | 2021 | 4811 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3578 | 0.030 |
Why?
|
CHO Cells | 2 | 2007 | 1387 | 0.030 |
Why?
|
Echocardiography | 1 | 2005 | 4989 | 0.030 |
Why?
|
Immunotherapy | 2 | 2019 | 4652 | 0.030 |
Why?
|
Stroke Volume | 1 | 2007 | 5496 | 0.030 |
Why?
|
Visual Cortex | 1 | 2021 | 1108 | 0.030 |
Why?
|
Proteomics | 1 | 2006 | 3848 | 0.030 |
Why?
|
DNA | 1 | 2006 | 7213 | 0.030 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 687 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 4176 | 0.030 |
Why?
|
Receptors, Virus | 1 | 2016 | 640 | 0.030 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 517 | 0.030 |
Why?
|
Cricetinae | 2 | 2007 | 2423 | 0.030 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 506 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4576 | 0.030 |
Why?
|
Research Design | 2 | 2005 | 6180 | 0.020 |
Why?
|
Stem Cells | 1 | 2005 | 3524 | 0.020 |
Why?
|
Monocytes | 1 | 2021 | 2570 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2015 | 732 | 0.020 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 619 | 0.020 |
Why?
|
Protein Conformation | 2 | 2013 | 3968 | 0.020 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3201 | 0.020 |
Why?
|
Natural Language Processing | 1 | 2020 | 1163 | 0.020 |
Why?
|
Codon | 1 | 2013 | 601 | 0.020 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12059 | 0.020 |
Why?
|
Exercise | 1 | 2008 | 5890 | 0.020 |
Why?
|
Cotinine | 1 | 2011 | 206 | 0.020 |
Why?
|
Health Status | 1 | 2004 | 4077 | 0.020 |
Why?
|
Infant | 2 | 2024 | 36193 | 0.020 |
Why?
|
Sequence Deletion | 2 | 2006 | 1494 | 0.020 |
Why?
|
Morpholines | 2 | 2005 | 581 | 0.020 |
Why?
|
Small Molecule Libraries | 1 | 2016 | 733 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3076 | 0.020 |
Why?
|
Virginia | 1 | 2010 | 116 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3156 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4281 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2371 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2017 | 1742 | 0.020 |
Why?
|
Point Mutation | 2 | 2006 | 1595 | 0.020 |
Why?
|
Child, Preschool | 2 | 2024 | 42232 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4544 | 0.020 |
Why?
|
Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2007 | 11530 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2005 | 678 | 0.020 |
Why?
|
Fibroblasts | 1 | 2020 | 4142 | 0.020 |
Why?
|
Calibration | 1 | 2012 | 818 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2008 | 5841 | 0.020 |
Why?
|
Macrophages | 1 | 2024 | 5767 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1745 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2009 | 3605 | 0.020 |
Why?
|
Phenotype | 2 | 2008 | 16592 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2046 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6032 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 270 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3767 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2013 | 2748 | 0.020 |
Why?
|
src-Family Kinases | 1 | 2011 | 535 | 0.020 |
Why?
|
Enzyme Activation | 2 | 2006 | 3597 | 0.020 |
Why?
|
Incidence | 1 | 2007 | 21355 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2011 | 547 | 0.020 |
Why?
|
Models, Statistical | 1 | 2003 | 5079 | 0.020 |
Why?
|
Therapeutic Irrigation | 1 | 2009 | 292 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2009 | 510 | 0.020 |
Why?
|
PC12 Cells | 1 | 2008 | 317 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1505 | 0.020 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18255 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7593 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2013 | 13446 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2007 | 287 | 0.020 |
Why?
|
Propensity Score | 1 | 2014 | 1913 | 0.020 |
Why?
|
Cell Adhesion | 2 | 2003 | 3088 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 17635 | 0.020 |
Why?
|
Graft Survival | 2 | 2008 | 3820 | 0.020 |
Why?
|
COS Cells | 1 | 2008 | 1130 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15601 | 0.020 |
Why?
|
Drug Resistance, Multiple | 1 | 2007 | 255 | 0.020 |
Why?
|
Butadienes | 1 | 2005 | 107 | 0.020 |
Why?
|
Norepinephrine | 1 | 2008 | 897 | 0.020 |
Why?
|
Transforming Growth Factor alpha | 1 | 2005 | 135 | 0.020 |
Why?
|
Cricetulus | 1 | 2007 | 814 | 0.020 |
Why?
|
Doxycycline | 1 | 2007 | 344 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7828 | 0.020 |
Why?
|
Metoprolol | 1 | 2005 | 90 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 22174 | 0.020 |
Why?
|
Models, Structural | 1 | 2005 | 340 | 0.020 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2005 | 108 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2011 | 1722 | 0.020 |
Why?
|
Propanolamines | 1 | 2005 | 163 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2020 | 14417 | 0.010 |
Why?
|
Genome-Wide Association Study | 2 | 2015 | 12690 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2008 | 1693 | 0.010 |
Why?
|
Cell Shape | 1 | 2005 | 371 | 0.010 |
Why?
|
Urogenital Neoplasms | 1 | 2005 | 131 | 0.010 |
Why?
|
Vincristine | 1 | 2007 | 1036 | 0.010 |
Why?
|
Genetics, Population | 1 | 2009 | 937 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2650 | 0.010 |
Why?
|
Purines | 1 | 2007 | 607 | 0.010 |
Why?
|
Gene Dosage | 1 | 2008 | 1218 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2009 | 1380 | 0.010 |
Why?
|
Mice, Transgenic | 2 | 2007 | 9542 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26202 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2008 | 1529 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3465 | 0.010 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2007 | 598 | 0.010 |
Why?
|
Paxillin | 1 | 2003 | 86 | 0.010 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 615 | 0.010 |
Why?
|
Organ Size | 1 | 2009 | 2254 | 0.010 |
Why?
|
Carbazoles | 1 | 2005 | 220 | 0.010 |
Why?
|
Metalloendopeptidases | 1 | 2005 | 393 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3358 | 0.010 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.010 |
Why?
|
Vasodilator Agents | 1 | 2007 | 973 | 0.010 |
Why?
|
Probability | 1 | 2008 | 2477 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6965 | 0.010 |
Why?
|
Flow Cytometry | 2 | 2005 | 5870 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2010 | 1787 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 2007 | 1386 | 0.010 |
Why?
|
Hot Temperature | 1 | 2009 | 1440 | 0.010 |
Why?
|
Cytodiagnosis | 1 | 2006 | 447 | 0.010 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2002 | 103 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 2004 | 1302 | 0.010 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 1762 | 0.010 |
Why?
|
Body Height | 1 | 2009 | 1570 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2008 | 15502 | 0.010 |
Why?
|
Hydroxamic Acids | 1 | 2005 | 481 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2005 | 750 | 0.010 |
Why?
|
Quinones | 1 | 2002 | 78 | 0.010 |
Why?
|
Nausea | 1 | 2005 | 679 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8656 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2004 | 784 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10774 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2004 | 931 | 0.010 |
Why?
|
Benzoquinones | 1 | 2002 | 198 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2005 | 496 | 0.010 |
Why?
|
Fibrinogen | 1 | 2004 | 888 | 0.010 |
Why?
|
Chemokines, CXC | 1 | 2002 | 422 | 0.010 |
Why?
|
Gene Frequency | 1 | 2008 | 3606 | 0.010 |
Why?
|
Age Factors | 2 | 2008 | 18399 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6770 | 0.010 |
Why?
|
Cell Size | 1 | 2002 | 624 | 0.010 |
Why?
|
Quinolines | 1 | 2006 | 765 | 0.010 |
Why?
|
Chemokine CXCL12 | 1 | 2002 | 454 | 0.010 |
Why?
|
Prednisone | 1 | 2005 | 1563 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2006 | 12973 | 0.010 |
Why?
|
Molecular Structure | 1 | 2005 | 1880 | 0.010 |
Why?
|
Genital Neoplasms, Female | 1 | 2005 | 532 | 0.010 |
Why?
|
World Health Organization | 1 | 2006 | 1322 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2012 | 3575 | 0.010 |
Why?
|
Doxorubicin | 1 | 2007 | 2224 | 0.010 |
Why?
|
Lactams, Macrocyclic | 1 | 2002 | 318 | 0.010 |
Why?
|
Nitriles | 1 | 2005 | 971 | 0.010 |
Why?
|
Health Policy | 1 | 2012 | 2684 | 0.010 |
Why?
|
Japan | 1 | 2004 | 1378 | 0.010 |
Why?
|
Rats | 2 | 2008 | 23741 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1866 | 0.010 |
Why?
|
Tissue Donors | 1 | 2009 | 2332 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2015 | 7859 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2003 | 1699 | 0.010 |
Why?
|
Societies, Medical | 1 | 2011 | 3905 | 0.010 |
Why?
|
Immunoblotting | 1 | 2002 | 1646 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2011 | 5493 | 0.010 |
Why?
|
Alternative Splicing | 1 | 2003 | 1093 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2009 | 2639 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2004 | 2358 | 0.010 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2005 | 954 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2003 | 1342 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 18966 | 0.010 |
Why?
|
Genetic Markers | 1 | 2004 | 2601 | 0.010 |
Why?
|
Antibodies | 1 | 2005 | 2418 | 0.010 |
Why?
|
Tyrosine | 1 | 2002 | 1440 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2872 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2010 | 3359 | 0.010 |
Why?
|
Anticoagulants | 1 | 2012 | 4812 | 0.010 |
Why?
|
Genome | 1 | 2004 | 1740 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2004 | 4615 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 2645 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2003 | 2448 | 0.010 |
Why?
|
Reactive Oxygen Species | 1 | 2002 | 2139 | 0.010 |
Why?
|
Kidney | 1 | 2009 | 7048 | 0.010 |
Why?
|
Hematologic Neoplasms | 1 | 2005 | 1896 | 0.010 |
Why?
|
Logistic Models | 1 | 2008 | 13255 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2004 | 3826 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2005 | 3879 | 0.010 |
Why?
|
Software | 1 | 2004 | 4434 | 0.010 |
Why?
|
Palliative Care | 1 | 2004 | 3598 | 0.000 |
Why?
|
Pregnancy | 1 | 2010 | 29890 | 0.000 |
Why?
|
Skin Neoplasms | 1 | 2005 | 5821 | 0.000 |
Why?
|
Quality of Life | 1 | 2005 | 13367 | 0.000 |
Why?
|